Inner Ear Diseases Market

Inner Ear Diseases: Novel Drug Delivery Approaches

  • Lowest Price Guaranteed From USD 1,899

  • Companies Covered
    135

  • Pages
    179

  • View Count
    8327

Inner Ear Diseases Market Overview

A significant proportion of the world’s population is suffering from otologic diseases. Absence of any disease modifying drugs is a big unmet need in the market. The current treatment of inner ear diseases is primarily based on counselling, electric and magnetic nerve stimulations. At the same time, there is a growing off-label use of drugs for symptomatic relief. Cochlear implants, brainstem implants and hearing aids are other commonly available options to the patients to overcome hearing damages. However, these options do suffer from several limitations such as high cost, poor sound quality, and painful surgeries (in case of implants). The widening gap between the demand and supply of drugs is likely to provide a major impetus to the market in the coming decade. The drugs for direct delivery to inner ear are currently under development and, once approved, are likely to gain a major share of the market.

Direct drug delivery to the inner ear is difficult due to the complex labyrinthine structure of the ear. However, with growing advances in technology and the increasing demands for specific drugs, direct inner ear drug delivery has become one of the key focus areas of researchers and companies across the world. The industry and university sponsored research is aimed at improving the current treatment regime and increasing the concentration of the drug in the inner ear for a promising treatment of otologic diseases. Specifically, intratympanic and intracochlear drug delivery routes are being explored by several stakeholders to devise efficient drug delivery strategies.

Cochlear implants (the only robust option currently available for permanent hearing loss) have also garnered increased attention worldwide. There are currently four established players: Cochlear Ltd., MED-EL, Advanced Bionics and Neurelec. However, the market is gradually opening up and newer players such as China‘s Hangzhou Nurotron have made efforts to come up with cost efficient implants. In addition, the industry has witnessed significant technological advancements with the introduction of water proof speech processors, prolonged battery life and compatibility with remote assistant. ‘Bio-Active’ drug eluting cochlear implants are also anticipatedto be available in the market in the near future.

Recent Developments in Inner Ear Diseases Market:

Several recent developments have taken place in the field of inner ear diseases. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In August 2023, Regeneron acquired Decibel Therapeutics in order to strengthen its gene therapy and hearing loss programs. 
  • In March 2023, Spiral Therapeutics acquired assets from Otonomy with an aim to boost inner ear disorders pipeline.  
  • In January 2023,  Spiral Therapeutics completed USD 8.25 million financing and initiated Phase 2 trial focusing on Meniere's Disease.

Scope of the Report

The ‘Inner Ear Diseases: Novel Drug Delivery Approaches, 2014 - 2025’ report provides an extensive study of the emerging market of drugs and cochlear implants for otologic diseases. The focus of this study is primarily on the drugs targeting inner ear diseases delivered through intratympanic and intracochlear routes; these drugs provide improved retention time, increase patient compliance, lower treatment cost and offer numerous other advantages. The report covers various aspects such as research pipeline (both industry and academia), technological improvements, sales potential and competitive landscape to assess new evolving opportunities. The study also identifies cochlear implants which are currently available in the market. We have provided a competitive spider web analysis to compare the various implants based on technical parameters (electrode length, electrode contact points etc.) and their user friendliness.

One of the key objectives of this report is to understand the current and future state of the recent advances in drugs and devices for inner ear diseases market. This is done by analyzing the following:

  • Drugs for inner ear delivery currently in the pipeline
  • Size of target consumer segments
  • Frequency of drug injections per year
  • Variable price points
  • Surgical intervention rates

In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The base year for the report is 2014. The report provides market forecasts for the period 2014 - 2025. The figures mentioned in this report are in USD, unless otherwise specified.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com